Table 1.
Demographic and clinical characteristics of participants for loss of chromosome Y study
| Control (n=214) |
Schizophrenia (n=146) |
P-value | |
|---|---|---|---|
| Age (years) (median [IQR]) | 58.5 [43.0–68.0] | 60.0 [49.0–68.0] | 0.125a |
| Smoking (never/former/current)b | – | 42/43/61 | – |
| Age of onset (years) (median [IQR]) | – | 25.0 [20.0–32.0] | – |
| Duration of illness (years) (median [IQR]) | – | 33.0 [18.0–42.0] | – |
| Antipsychotic dose (mg/day) (median [IQR])c | – | 675.0 [375.0–1,250.0] | – |
| GAF score (mean ± SD) | – | 38.0±7.7 | – |
| BPRS score (median [IQR]) | – | 42.0 [39.0–53.0] | – |
| Presence of LOY (with LOY/without LOY) | 18/196 | 13/133 | 0.851d |
Notes: Accurate information regarding age of onset and duration of illness was available from the clinical records of 145 of 146 patients with schizophrenia. Accurate information regarding GAF and BPRS scores were available from the clinical records of 69 of 146 patients with schizophrenia.
P-value between schizophrenia and control groups calculated using Mann–Whitney U-test.
For smoking status, “never” refers to an individual who has never been a cigarette or cigar smoker, while “former” indicates an individual who had smoked in his lifetime but who was not a smoker at the time of blood sampling, and “current” refers to an individual who was a smoker at the time of blood sampling.
Antipsychotic dose was calculated based on chlorpromazine equivalents.
P-value between individuals with and without LOY calculated using Fisher’s exact test.
Abbreviations: IQR, interquartile range; LOY, loss of chromosome Y; GAF, Global Assessment of Functioning; BPRS, Brief Psychiatric Rating Scale.